Sil-P (Silymarin + Phosphatidyl Choline)
Sil-P (Silymarin + Phosphatidyl Choline)

Sil-P (Silymarin + Phosphatidyl Choline)

Regular price
₱27.50
Sale price
₱25.00
Tax included. Shipping calculated at checkout.
Quantity must be 1 or more

The high prevalence of liver diseases such as chronic hepatitis and cirrhosis underscores the need for efficient and cost-effective treatments. The potential benefit of silymarin (extracted from the seeds of Silybum marianum or milk thistle) in the treatment of liver diseases remains a controversial issue.

Silymarin has metabolic and cell-regulating effects at concentrations found in clinical conditions, namely carrier-mediated regulation of cell membrane permeability, inhibition of the 5-lipoxygenase pathway, scavenging of reactive oxygen species (ROS) of the R-OH type and action on DNA-expression, for example, via suppression of nuclear factor (NF)-kappaB.

Pooled data from case record studies involving patients with Amanita phalloides poisoning show a highly significant difference in mortality in favour of silibinin [the main isomer contained in silymarin].

The available trials in patients with toxic (e.g. solvents) or iatrogenic (e.g. antispychotic or tacrine) liver diseases, showed an improved clinical tolerance of tacrine.

In spite of some positive results in patients with acute viral hepatitis, no formally valid conclusion can be drawn regarding the value of silymarin in the treatment of these infections.

Although there were no clinical end-points in the four trials considered in patients with alcoholic liver disease, histological findings were reported as improved in two out of two trials, improvement of prothrombin time was significant (two trials pooled) and liver transaminase levels were consistently lower in the silymarin-treated groups.

Therefore, silymarin may be of use as an adjuvant in the therapy of alcoholic liver disease. Analysis was performed on patients with liver cirrhosis. The evidence shows that, compared with placebo, silymarin produces a nonsignificant reduction of total mortality; but that, on the other hand, the use of silymarin leads to a significant reduction in liver-related mortality. An individual trial reported a reduction in the number of patients with encephalopathy.

In one study of patients with cirrhosis-related diabetes mellitus, the insulin requirement was reduced.

We conclude that available evidence suggests that silymarin may play a role in the therapy of (alcoholic) liver cirrhosis. Silymarin is has a good safety record and only rare case reports of gastrointestinal disturbances and allergic skin rashes have been published.